bitcoin currency price, Featured snippets

Domestic futures fell more and rose less, No.20 rubber fell nearly 3%, domestic futures fell more and rose less, No.20 rubber fell nearly 3%, Shanghai Bank and BR rubber fell nearly 2%, and rubber, caustic soda, vegetable oil, rapeseed meal, hot coil, international copper and pulp fell more than 1%. In terms of increase, Shanghai nickel and alumina rose by over 1%, while SC crude oil and palm oil rose by nearly 1%.Hailian Jinhui invested 20 million yuan to set up an auto parts company in Wuhu. According to the enterprise search APP, Wuhu Hailian Jinhui Auto Parts Co., Ltd. was established recently, with the legal representative of Wang Weichao and the registered capital of 20 million yuan. Its business scope includes: manufacturing of auto parts and accessories; Mold manufacturing; Sales of metal materials; New material technology research and development, etc. Enterprise investigation shows that the company is indirectly wholly-owned by Hailian Jinhui.Treasury bond futures opened, with 30-year main contracts rising by 0.48%, 10-year main contracts rising by 0.36%, 5-year main contracts rising by 0.25% and 2-year main contracts rising by 0.05%.

Shanghai Securities: The pharmaceutical and bio-industry is expected to further repair its performance and valuation. The Shanghai Securities Research Report pointed out that with the support of policies and the adjustment of the internal structure of the industry, the pharmaceutical and bio-industry is expected to further repair its performance and valuation. It is suggested to pay attention to five directions: 1) Innovative drugs (with strong national policy support, the payment terminal is expected to further improve and go to sea to occupy the global market); 2)CXO (the negative impact of the biosafety bill event has been eliminated, and the demand for orders in the superimposed interest rate reduction cycle has increased, which is expected to usher in a double repair of performance and valuation); 3) Imitation and innovation (centralized procurement is expected to clear up, increase innovation, and traditional pharmaceutical companies will usher in new opportunities); 4) Traditional Chinese Medicine (the national policy supports the innovation of traditional Chinese medicine, and its performance is expected to maintain a good growth rate); 5) Medical devices (equipment updating, high-consumption innovation, low-consumption going to sea, etc.). Individual stocks can be concerned about: Baekje Shenzhou, Wuxi PharmaTech, China Resources Sanjiu and so on.The application direction of AI fell in early trading, with Jincai Internet falling more than 8%, followed by Tianyu Digital, Huayang Lianzhong, Fushi Holdings, Aofei Entertainment and Fengyuzhu.The growth enterprise market index fell to 1%, the Shanghai Composite Index fell by 0.65% and the Shenzhen Composite Index fell by 0.93%. Securities, real estate and food consumption were among the top losers, with nearly 4,300 stocks falling in Shanghai, Shenzhen and Beijing.

Rambler: We have always taken a proactive attitude towards all kinds of co-branded products. rambler said at the shareholders' reception day on December 12 that the company has always taken a proactive attitude towards all kinds of co-branded products, and the future co-branded products will be deeper and closer.Solar energy and other new companies have set up photovoltaic power generation equipment business. The enterprise search APP shows that recently, China Energy Saving Ledebao Solar Technology (Delingha) Co., Ltd. was established, with Du Hu as the legal representative and a registered capital of 1 million yuan. Its business scope includes: sales of solar thermal utilization equipment; Lease of photovoltaic power generation equipment; Ecological restoration and ecological protection services, etc. Enterprise investigation shows that the company is jointly owned by China Energy Saving Solar Technology Co., Ltd. and Qinghai Laidebao New Materials Co., Ltd., a wholly-owned subsidiary of solar energy.Shanghai Securities: The pharmaceutical and bio-industry is expected to further repair its performance and valuation. The Shanghai Securities Research Report pointed out that with the support of policies and the adjustment of the internal structure of the industry, the pharmaceutical and bio-industry is expected to further repair its performance and valuation. It is suggested to pay attention to five directions: 1) Innovative drugs (with strong national policy support, the payment terminal is expected to further improve and go to sea to occupy the global market); 2)CXO (the negative impact of the biosafety bill event has been eliminated, and the demand for orders in the superimposed interest rate reduction cycle has increased, which is expected to usher in a double repair of performance and valuation); 3) Imitation and innovation (centralized procurement is expected to clear up, increase innovation, and traditional pharmaceutical companies will usher in new opportunities); 4) Traditional Chinese Medicine (the national policy supports the innovation of traditional Chinese medicine, and its performance is expected to maintain a good growth rate); 5) Medical devices (equipment updating, high-consumption innovation, low-consumption going to sea, etc.). Individual stocks can be concerned about: Baekje Shenzhou, Wuxi PharmaTech, China Resources Sanjiu and so on.